Focuses on R&D and manufacturing, and meets PIC/S and FDA regulations

    Orient Pharma (OP), focusing on R&D and manufacturing and established on Feb 1, 2008, is the subsidiary of Orient Europharma(OEP). Located in Yunlin county in the central of Taiwan, the plant was completely constructed in 2010 Q2. The Yunlin plant obtained the approval for PIC/S GMP from the Taiwan FDA in July, 2011. In addition, it received “Accreditation Certificate of Foreign Drug Manufacturer” from Japan Ministry of Health, Laboar, and Welfare (MHLW) in April, 2012. Furthermore, the Yunlin plant passed the cGMP site inspection by US FDA in April 2013.

    Orient Pharma actively applies for drug registration and new drug development in the United States. We focus on development of new drugs which fulfill the standards set by US FDA, including anti-psychotics, drugs for treating Alzheimer’s disease, psychostimulants, and drugs for treating Parkinson’s disease. In addition, Orient Pharma collaborates with many R&D oriented companies from EU, the United States, and Japan to develop new drugs. At the same time, we are also devoted to patent application to protect our intellectual property.

Owns plenty of R&D technologies and patents

Currently 5 new drug delivery technologies are being developed: